|
Delayed
Nasdaq
00:00:00 24/06/2026 +04
|
5-day change | 1st Jan Change | ||
| 40.50 USD | +0.80% |
|
-.--% | +61.94% |
| 06-24 | Swiss Market Index Extends Rally; OC Oerlikon Shares Gain | MT |
| 06-24 | Eli Lilly Completes Acquisition of Centessa Pharmaceuticals | MT |
Company Valuation: Centessa Pharmaceuticals plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 1,012 | 293.2 | 777.1 | 2,208 | 3,653 |
| Change | - | -71.03% | 165.01% | 184.18% | 65.43% |
| Enterprise Value (EV) 1 | 492.9 | -30.6 | 605.7 | 1,844 | 3,477 |
| Change | - | -106.21% | 2,079.61% | 204.46% | 88.56% |
| P/E | -2.22x | -1.34x | -5.07x | -8.13x | -17.2x |
| PBR | 2.06x | 0.87x | 3.33x | 5.53x | 7.08x |
| PEG | -0x | 0x | 0.2x | -0.3x | 0.6x |
| Capitalization / Revenue | - | - | 113,399,910x | - | 243,556,955x |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -3.54x | 0.15x | -3.54x | -9.17x | -16.7x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -5.07 | -2.315 | -1.571 | -2.059 | -1.455 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | 6.853 | - | 15 |
| EBITDA | -139.3 | -207.2 | -171 | -200.7 | -207.4 |
| EBIT 1 | -139.3 | -207.3 | -171.3 | -201.1 | -207.7 |
| Net income 1 | -381.9 | -216.2 | -151.1 | -235.8 | -197.5 |
| Net Debt 1 | -519.4 | -323.8 | -171.5 | -364.3 | -176.2 |
| Reference price 2 | 11.26 | 3.10 | 7.96 | 16.75 | 25.01 |
| Nbr of stocks (in thousands) | 89,901 | 94,596 | 97,629 | 131,845 | 146,076 |
| Announcement Date | 30/03/22 | 30/03/23 | 28/03/24 | 24/03/25 | 31/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 6.27B | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 18.13x | 28.02x | 6.57x | 0.34% | 40.06B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CNTA Stock
- Valuation Centessa Pharmaceuticals plc
Select your edition
All financial news and data tailored to specific country editions
